We deliver professional, process-driven plant engineering design solutions dedicated exclusively to Antibody-Drug Conjugate (ADC) commercial manufacturing. ADC production integrates monoclonal antibody biosynthesis, cytotoxic drug handling, linker conjugation, purification and finished formulation, featuring high toxicity, complex workflows and ultra-stringent contamination control requirements. Our tailored plant design addresses the unique dual risks of biologic impurity cross-contamination and small-molecule cytotoxic exposure, building standardized, fully isolated and audit-ready manufacturing facilities for clinical batch production and large-scale commercial launch of ADC antibody drugs.
Our ADC plant engineering adopts a scientifically partitioned dual-process layout to separate biologic antibody production, small-molecule toxin preparation and core conjugation workflows. We implement strict physical isolation, independent air handling systems and graded differential pressure zoning to eliminate cross-contamination between raw antibodies, cytotoxic payloads and conjugated intermediates. Optimized closed-loop material transfer and fully enclosed operational zones minimize personnel exposure risks and product loss. The integrated layout seamlessly connects upstream cell culture, downstream antibody polishing, conjugation reaction, impurity removal and sterile filling, ensuring continuous, stable and repeatable ADC manufacturing workflows.
All engineering design specifications, facility configurations and safety control systems strictly comply with FDA, EMA and global cGMP guidelines for complex targeted anticancer biotherapeutics. We deploy dedicated toxin waste treatment systems, high-efficiency exhaust purification and residual substance elimination mechanisms to achieve zero-risk toxic material management. All production rooms, sanitary pipelines and utility systems support standardized CIP/SIP sterilization and full environmental monitoring. We provide complete DQ, IQ, OQ and PQ validation packages and full-traceability technical documentation, ensuring long-term compliant operation and smooth regulatory audit approval for ADC manufacturing plants.
Engineered for ADC product iteration and phased capacity expansion, our plant engineering design adopts flexible modular and expandable architecture. The scalable framework supports rapid switching of different ADC pipeline products and incremental production capacity upgrading without overall facility reconstruction. Highly automated closed production and intelligent safety monitoring systems reduce manual intervention and operational risks, lowering comprehensive manufacturing costs. We deliver safe, compliant and future-proof ADC plant engineering solutions to accelerate industrial transformation and stabilize high-quality commercial production of targeted antibody-drug conjugate therapeutics.
